Nimenrix

Meningococcal (A, C, W-135, Y) conjugate vaccine, the active ingredient in Nimenrix, is a vaccine presented as a 0.5 mL injectable solution for intramuscular use. It is indicated for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y in individuals from 2 months up to 55 years of age.

GNH USA supplies Nimenrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Nimenrix is a conjugate vaccine that targets meningococcal polysaccharides to prevent invasive disease. It is used in the following clinical situations: - Invasive meningococcal disease (A, C, W-135, Y): Provides active immunity to prevent infection by these serogroups. - Primary vaccination (children ≥2 months): Establishes protective antibody levels in the pediatric population. - Booster immunization (adolescents and adults): Restores waning immunity and maintains long‑term protection.

Nimenrix is generally well tolerated, but injection‑related and systemic reactions can occur.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild to moderate headache within 24 hours. - Fatigue: temporary tiredness post‑vaccination. - Myalgia: mild muscle aches.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder. - Seizures: infrequent convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Acute allergic reaction: angioedema or urticaria. - Vaccine‑associated meningococcal disease: extremely rare occurrence.

Before administering Nimenrix, consider the following precautions: - Pregnancy: safety not established; evaluate risk‑benefit with a healthcare professional. - Breastfeeding: unknown safety profile; weigh potential benefits against risks. - Age limitation: not recommended for individuals older than 55 years. - Known allergy: avoid if hypersensitivity to any vaccine component is documented. - Immunocompromised patients: may exhibit reduced antibody response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other therapies; monitor accordingly.

Major Interactions (Avoid): - Severe allergic reaction to any vaccine component: contraindicates use. - Prior anaphylaxis to a meningococcal conjugate vaccine: contraindicates administration.

Moderate Interactions (Monitor Closely): - Concurrent administration of blood products containing immunoglobulins: may diminish vaccine efficacy. - Live bacterial vaccines given within 4 weeks: could interfere with immune response. - High‑dose corticosteroids started within 2 weeks: may impair antibody generation. - Use of antipyretics before vaccination: may blunt antibody response. - Simultaneous receipt of other vaccines: generally safe but may increase local reactogenicity.